Wyeth Seeks Silver Lining In Series Of Regulatory Setbacks
Wyeth believes that offering a lower dose of its serotonin-norepinephrine reuptake inhibitor Pristiq will better position the drug to compete in the major depressive disorder market
Wyeth believes that offering a lower dose of its serotonin-norepinephrine reuptake inhibitor Pristiq will better position the drug to compete in the major depressive disorder market